The Role of Neoadjuvant Chemotherapy in Non-SCC of the Cervix: A Systematic Review
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 10, Pages 2761-2776
AbstractCervical cancer is the third most common cancer in women and the most significant cause of CC is HPV infection. One of the treatment methods for cervical cancer is pre-surgery neoadjuvant chemotherapy (NACT), which is performed to reduce the size of the tumor, facilitate the surgical process, and improve the survival of patients with this cancer. The present study is a systematic review conducted by searching the databases of Elsevier, PubMed Springer, and Wiley, and with the keywords of Cervix cancer, Adenocarcinoma, Adenosquamous carcinoma, and Neoadjuvant chemotherapy; studies conducted between 1998-2020 were reviewed. Out of a total of 1018 articles, 15 articles were selected for further review, considering the inclusion/exclusion criteria. The results showed that the use of NACT improved the patient's physical condition, reduced tumor size, reduced metastasis, facilitated surgery, and improved survival; also, it was associated with successful delivery without side effects in infants. However, further studies are needed to further understand the effect of this treatment in non-scc cancers.
- Article View: 46
- PDF Download: 90